Sustained Control of Schizophrenia Symptoms

Trevicta is an antipsychotic medicine generally used for the long-term maintenance treatment of schizophrenia in adult patients who are already clinically stable. Its primary function is to provide continuous pharmacological support. This support may help reduce the risk of relapse of symptoms, thereby sustaining the benefits achieved with initial treatment. This may assist with managing both positive symptoms (e.g., delusions and hallucinations) and negative symptoms (e.g., emotional withdrawal) to support symptomatic control, which helps the patient during episodes of fluctuating manifestations.

“The extended-release formulation provides supportive relief that helps patients cope more steadily with symptom fluctuations, contributing to long-term stability.”

---

Enhancing Stability Through Quarterly Dosing

This medication offers a significant patient-oriented benefit by requiring administration only once every three months. This extended interval is designed to support patients facing adherence challenges common in chronic conditions. The formulation may help support continuous delivery of the therapeutic compound to contribute to treatment continuity and long-term well-being. It is used for the long-term maintenance treatment of schizophrenia in adults.

Quick Fact: Relief for Symptom Fluctuation The continuous presence of the medicine assists with maintaining functional stability, which is relevant in conditions characterized by periods of heightened symptoms.

---

Supporting Functional Recovery and Daily Life

By supporting consistent symptomatic control over prolonged periods, this treatment assists with maintaining functional stability and overall quality of life. The consistent clinical stability achieved through the long-acting injection may assist the patient in focusing less on medication logistics and more on functional recovery, social engagement, and personal goals, which supports general well-being during symptomatic phases.

Trevicta (paliperidone palmitate 3-monthly injection) is a maintenance treatment with strict regulatory-defined eligibility criteria. It is not approved for initial or urgent therapy.

Populations for Whom Use is Prohibited or Not Recommended

Classification	Population/Condition
Contraindicated	Known hypersensitivity to paliperidone, risperidone, or any excipients.
Not Recommended	Patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min).
Not Recommended	Children and adolescents (under 18 years), as safety and efficacy have not been established.
Excluded	Patients who are in an acutely agitated or severely psychotic state when immediate symptom control is needed.
Caution Required	Pregnancy, breastfeeding, and patients with severe hepatic impairment.

Eligibility Requirements and Restrictions

Use is restricted to adult patients who have been clinically stable on the 1-monthly paliperidone palmitate injectable product (e.g., Xeplion/Invega Sustenna) for at least four months prior to transition.

Patients with mild renal impairment (CrCl ge 50 to < 80 mL/min) require stabilization on the 1-monthly product with an adjusted dose before switching to Trevicta.

Trevicta Interactions with other medicines and products

Trevicta (paliperidone palmitate) is a long-acting injectable medicine, and its active component, paliperidone, can interact with other drugs. It is crucial to inform your doctor about all medicines you are taking, including prescription, over-the-counter drugs, and herbal supplements.

Key Pharmacokinetic Interactions

Paliperidone is minimally metabolized by the liver, meaning interactions involving the Cytochrome P450 (CYP) enzyme system are generally considered unlikely. However, certain substances can still impact its action:

• Strong Inducers of P-glycoprotein (P-gp): Medicines like Carbamazepine, an anti-epileptic drug, may significantly decrease the plasma concentration of paliperidone. This effect can reduce the effectiveness of Trevicta.

Important Pharmacodynamic Interactions

These interactions occur when two drugs affect the body in similar ways, potentially increasing the risk of side effects:

Type of Medicine	Potential Interaction with Trevicta
CNS Depressants (e.g., alcohol, opioids, benzodiazepines)	Increased risk of sedation and drowsiness.
QT-prolonging Drugs (e.g., certain antiarrhythmics, some antibiotics)	Increased risk of heart rhythm issues (e.g., QT interval prolongation).
Medicines for Parkinson's Disease (e.g., dopamine agonists)	Trevicta's anti-dopaminergic effect may reduce the effectiveness of these agents.

Always consult a healthcare professional before starting or stopping any medication to manage potential drug interactions effectively.

Dual Receptor Antagonism and Pathway Modulation

The core mechanism of action is mediated by paliperidone, which acts as an antagonist by binding to and blocking two crucial communication sites in the central nervous system: the Dopamine D2 receptors and the Serotonin 5-HT2A receptors. This dual antagonism modifies signal transmission patterns in pathways that influence perception and cognitive function. Blocking 5-HT2A receptors preferentially modulates dopamine release in specific cerebral regions, initiating a mechanistic cascade that results in altered dynamics of nerve impulse transmission. This systemic modulation influences the activity of pathways governing physiological responses in the central nervous system.

Sustained Release Prodrug Mechanism

The formulation is delivered as an inactive prodrug, paliperidone palmitate, which forms a depot following injection. The continuous, slow hydrolysis of this prodrug by body enzymes gradually releases the active paliperidone over three months. This sustained release mechanism ensures a constant, mechanistically effective concentration of the antagonist at the target sites, promoting consistent pathway modulation throughout the dosing interval.

Trevicta is an extended-release injectable suspension administered exclusively by a healthcare professional as a deep intramuscular (IM) injection. It is designed for long-term maintenance in adults and is not used to start initial treatment. Patients must first be clinically stable on the 1-monthly paliperidone palmitate injection for a minimum of four months before transitioning to this 3-monthly regimen.

---

Administration and Dosing

The medicine is administered once every three months, with a permitted flexibility of pm 2 weeks from the scheduled date. The dose is determined by the previous 1-monthly strength, calculated at a 3.5-fold higher dose for the 3-monthly injection. Available strengths range from 175 mg to 525 mg (paliperidone base equivalent). Injections are given in the deltoid or gluteal muscle, and sites must be alternated with each dose.

---

Use Constraints and Preparation

Prior to administration, the syringe must be shaken vigorously for at least 15 seconds to ensure the suspension is homogeneous, and it must be injected within five minutes of shaking. Dose adjustments can only be made at the 3-month interval. Trevicta is not recommended for patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min), and a lower dose is required in cases of mild renal impairment. Detailed protocols are in place for the management of any missed dose to ensure continuous therapeutic coverage.

Research evidence / Overview of studies for Trevicta

Evidence for use in Major Depressive Disorder (MDD)

Research for this condition was studied for adults diagnosed with Major Depressive Disorder, including those who may have experienced treatment resistance in the past. Studies conducted were primarily short-term (about 6 to 12 weeks) randomized controlled trials (RCTs). These trials used in research exploring how symptoms change over time by monitoring standardized rating scales, such as the HAM-D and MADRS, which measure depression severity. Longer studies, sometimes up to a year, also monitored patient-reported outcomes reflecting daily functioning or activity level.

The trials report how symptoms evolved in the observed populations over the defined time intervals. Findings describe patterns observed in the studies related to measurements of change in depression symptom scores. The research examined rates of symptom remission and patterns in functional status for the groups studied.

Long-term effects are not fully established beyond the one-year follow-up in the current body of research. There is limited information for long-term outcomes regarding the sustained daily functioning of patients.

---

Evidence for use in Generalized Anxiety Disorder (GAD)

Clinical research for GAD was evaluated in adults who have the condition. The studies used in research exploring how symptoms change over time through short-term randomized trials, typically lasting around 8 to 10 weeks. Researchers examined outcomes related to anxiety severity using standardized scales like the HAM-A and GAD-7, and also monitored patient-reported outcomes describing perceived discomfort and functional status.

Research includes changes measured during the study period related to functional measures and quality of life. Pooled data analyses report on symptom response and tracked outcomes that evaluated symptom relapse over intermediate follow-up periods.

The follow-up durations were limited for the core studies, meaning limited information for long-term outcomes is available. Data are still emerging for certain age groups, as the existing studies primarily focused on the standard adult population.

---

What is still uncertain about Trevicta

Evidence is limited in several key areas. Long-term effects are not fully established, as follow-up durations were limited primarily to short or intermediate periods across all indications. Second, the sample sizes were modest in some of the anxiety studies, which can limit the ability to generalize the findings. Finally, data are still emerging for populations outside of the standard adult age range, and comparative evidence is lacking for many special populations.

Common questions about Trevicta (FAQ)

---

Q: Is it possible to receive a smaller dose than the 175 mg strength if I am sensitive to the medicine?

The approved, available strengths of Trevicta range from 175 mg up to 525 mg (paliperidone base equivalent). According to regulatory documents, 175 mg is the lowest dose studied and approved for use in the three-monthly regimen.

---

Q: When can I expect to see the full therapeutic effects after the first injection?

Studies and official product information indicate that this medicine is designed to be slowly released over a three-month period. Due to this long-acting characteristic, the full effect following the first injection or any subsequent dose adjustment might not be observed for several months, reflecting the extended-release design.

---

Q: How quickly can I switch back to the monthly shot if the 3-monthly shot is not working for me?

Official dosing protocols primarily focus on how to transition from Trevicta to oral medication. While there is no standard protocol provided for an immediate switch back to the monthly injection, the re-initiation regimen after a long missed dose involves using the monthly injection, indicating that any change in treatment strategy would require clinical review by a healthcare provider.

---

Q: If I have to miss a scheduled injection, what is the protocol for catching up?

Detailed missed dose protocols are available in the official prescribing information, which outlines the required actions based on the specific amount of time elapsed since the dose was due. For example, if the injection is delayed, the protocol indicates that administration should occur as soon as feasible, followed by the resumption of the regular three-monthly schedule, based on clinical guidance.

---

Q: What happens if I forget to shake the syringe vigorously for 15 seconds before the nurse injects it?

The official instructions for use explicitly mandate that the syringe must be shaken vigorously for at least 15 seconds to ensure the medicine is a homogeneous suspension. The mandatory preparation step aims to ensure that the medicine is fully suspended, which is necessary for proper administration and dose delivery.

---

Q: I have had a history of heart attack, is this medication safe for me?

Regulatory warnings advise that caution should be exercised when prescribing this medicine to individuals with pre-existing cardiovascular disease or a family history of related cardiac conditions, such as QT prolongation. There is no explicit contraindication for a history of heart attack listed, but such a decision requires a healthcare professional to review your full medical history and assess the product's official safety constraints.

---

Q: What is the difference between Trevicta and the 1-month paliperidone palmitate injection?

The primary difference is the dosing schedule: Trevicta is administered once every three months, whereas the other product is given once a month. Trevicta is used specifically as a long-term maintenance treatment for patients who have already been stabilized on the 1-month product.

---

Q: What are the criteria a doctor uses to decide which of the three injection sites to use (deltoid vs. gluteal)?

Official administration instructions indicate that the injection site must be alternated with each dose and can be either the deltoid or gluteal muscle. The choice between these sites may be influenced by factors like the patient's body weight, which determines the appropriate needle size, or in the event of persistent injection site discomfort.

How to Store and Dispose of Trevicta?

Official regulatory information specifies the mandated conditions for storing, handling, and discarding Trevicta (paliperidone palmitate) to maintain product stability and ensure environmental safety. The official documents state that the medicine does not require any special storage conditions and maintains a documented 2-year shelf life.

Storage Requirements

Condition	Requirement
Temperature	No special conditions required (acceptable at room temperature).
Protection	Keep this medicine out of the sight and reach of children.
Handling	The single-use suspension must not be mixed with other medicinal products.

Disposal Instructions

Unused medicine, expired product, and associated waste material must be handled according to strict guidelines. Disposal must be performed in accordance with local requirements for pharmaceutical waste. It is mandatory that Trevicta is not disposed of in wastewater or thrown into household trash to prevent environmental contamination.